Pending Decision On First US OTC Birth Control Shines Spotlight On Self-Report Study Data
Executive Summary
Approval likely would account for all weight on scale of FDA decision if not for self-report element in design of HRA Pharma’s actual use study for OTC switch of 0.075-mg norgestrel branded Opill. HRA’s sNDA offers lesson for using electronic diary apps in self-report studies.